HIPV3/EboGP aerosol HIPV3/EboGP IN/IT HPIV3 VRP
... cell responses) and mucosal responses that can be accelerated with a second dose. Aerosolized vaccine confered cross-protection and can protect against viral hemorrhagic fever. Aerosolized vaccine can be easly implemented in case of an outbreak, or during bioterrorism and warfare scenarios. ...
... cell responses) and mucosal responses that can be accelerated with a second dose. Aerosolized vaccine confered cross-protection and can protect against viral hemorrhagic fever. Aerosolized vaccine can be easly implemented in case of an outbreak, or during bioterrorism and warfare scenarios. ...
Detailed non-confidential information about this
... therapeutic vaccine against PML. It is derived from the major capsid protein VP1 of the human John Cunningham virus (JCV). JCV is a ubiquitous virus that exclusively infects humans. About 50-90% of adults are infected with JCV without clinical symptoms associated with the infection. However, JCV may ...
... therapeutic vaccine against PML. It is derived from the major capsid protein VP1 of the human John Cunningham virus (JCV). JCV is a ubiquitous virus that exclusively infects humans. About 50-90% of adults are infected with JCV without clinical symptoms associated with the infection. However, JCV may ...
Protection of Travelers
... high cost and the extended course of doses are major inhibitors of its wide use in travelers. Influenza and pneumococcal infection. Persons considered at high risk of contracting influenza who are traveling to areas of the world where influenza is epidemic should receive influenza vaccine. Pneumococ ...
... high cost and the extended course of doses are major inhibitors of its wide use in travelers. Influenza and pneumococcal infection. Persons considered at high risk of contracting influenza who are traveling to areas of the world where influenza is epidemic should receive influenza vaccine. Pneumococ ...
Sperm-based contraceptive vaccine for wild rabbit
... Fertility control is one option for managing pest species [1]. Many laboratory studies have shown that parenteral (injection) immunisation with specific reproductive antigens can lead to a reduction in fertility [2]. World-wide there is considerable interest in the development of contraceptive vacci ...
... Fertility control is one option for managing pest species [1]. Many laboratory studies have shown that parenteral (injection) immunisation with specific reproductive antigens can lead to a reduction in fertility [2]. World-wide there is considerable interest in the development of contraceptive vacci ...
Recent progress in vaccines
... include the lack of good quality vaccine formulations and the absence of mass market appeal, with the latter being complicated by the high cost of clinical investigations. However, this situation is rapidly changing by increasing medical need and the attention of both investigators and industry repr ...
... include the lack of good quality vaccine formulations and the absence of mass market appeal, with the latter being complicated by the high cost of clinical investigations. However, this situation is rapidly changing by increasing medical need and the attention of both investigators and industry repr ...
HIV Treatment Updates - Maine Pharmacy Association
... – genotype (detects mutations that confers HIV drug resistance) – Phenotype (culture based on viral replication assays in the absence or presence of drugs) ...
... – genotype (detects mutations that confers HIV drug resistance) – Phenotype (culture based on viral replication assays in the absence or presence of drugs) ...
phase ii safety and immunogenicity study of live
... with one CHIK strain leads to protection against all strains.18 Reciprocal cross-protection after infection with other alphaviruses occurs in animal models,19,20 although it is unclear if similar cross protection occurs in humans sequentially exposed to natural infection or live alphavirus vaccines. ...
... with one CHIK strain leads to protection against all strains.18 Reciprocal cross-protection after infection with other alphaviruses occurs in animal models,19,20 although it is unclear if similar cross protection occurs in humans sequentially exposed to natural infection or live alphavirus vaccines. ...
Infectious Bursal Disease: Pathogenicity and
... lymphocyte depletion in bursal follicles (Muller et al., 1979). The infection with IBDV may exacerbate previous infections with other infectious agents, and may reduce the capacity of the bird to respond to vaccination, as the virus damages the humoral and cellular immune responses of chickens (Shar ...
... lymphocyte depletion in bursal follicles (Muller et al., 1979). The infection with IBDV may exacerbate previous infections with other infectious agents, and may reduce the capacity of the bird to respond to vaccination, as the virus damages the humoral and cellular immune responses of chickens (Shar ...
Recommendations of advisory committee on immunization practices
... k) Functional or anatomic asplenia(•) (*) Vaccination recommended even in the case of previous vaccination for any indication, and should be administered no less than 5 years after the previous dose (•) Revaccination recommended 5 years after the first dose PCV13, a 13-valent conjugate pneumococcal ...
... k) Functional or anatomic asplenia(•) (*) Vaccination recommended even in the case of previous vaccination for any indication, and should be administered no less than 5 years after the previous dose (•) Revaccination recommended 5 years after the first dose PCV13, a 13-valent conjugate pneumococcal ...
Limitations of Antiretroviral Therapy
... Mutations Occur Spontaneously in the HIV Genome HIV makes copies of itself very rapidly ~ 1-10 billion new virus particles/day During its replication, HIV is prone to make errors when ...
... Mutations Occur Spontaneously in the HIV Genome HIV makes copies of itself very rapidly ~ 1-10 billion new virus particles/day During its replication, HIV is prone to make errors when ...
Recognizing the Value of Innovation in HIV/AIDS Therapy
... 30 treatment options for HIV have been developed since 1987, arming physicians with increasingly more therapeutic options that support these kinds of improvements in patient survival.6 Over time, moving from the pre-HAART era in which no HAART regimens were available, to the early- and then late-HAA ...
... 30 treatment options for HIV have been developed since 1987, arming physicians with increasingly more therapeutic options that support these kinds of improvements in patient survival.6 Over time, moving from the pre-HAART era in which no HAART regimens were available, to the early- and then late-HAA ...
Guidelines for the Use of Antiretroviral Agents in Adults
... Transmission via injection drug use is second most common transmission route in the U.S. Injection drug users (IDU) Often have multiple comorbidities, Increased morbidity and mortality, Decreased access to HIV care Are less likely to receive ARV ...
... Transmission via injection drug use is second most common transmission route in the U.S. Injection drug users (IDU) Often have multiple comorbidities, Increased morbidity and mortality, Decreased access to HIV care Are less likely to receive ARV ...
Design of new vaccines in the genomic and post
... the in silico analysis of a single genome, became evident when Reverse Vaccinology was applied to the Gram-positive microorganism Streptococcus agalactiae (also known as Group B Streptococcus (GBS)). This bacterium is one of the leading causes of bacterial sepsis, pneumonia and meningitis in neonate ...
... the in silico analysis of a single genome, became evident when Reverse Vaccinology was applied to the Gram-positive microorganism Streptococcus agalactiae (also known as Group B Streptococcus (GBS)). This bacterium is one of the leading causes of bacterial sepsis, pneumonia and meningitis in neonate ...
CFAR research in progress talk
... Alternative – Effective but have potential disadvantages – May be the preferred regimen in individual patients Acceptable – Less virologic efficacy, lack of efficacy data, or greater toxicities ...
... Alternative – Effective but have potential disadvantages – May be the preferred regimen in individual patients Acceptable – Less virologic efficacy, lack of efficacy data, or greater toxicities ...
Update on herpes zoster vaccination
... had HZ? Having an episode of HZ has an immunizing effect, greatly reducing the probability of a second event. 16 That said, patients with a history of severe HZ are often the most insistent on receiving the vaccine,17 and concerns have been raised about the validity of patient histories of HZ. For ...
... had HZ? Having an episode of HZ has an immunizing effect, greatly reducing the probability of a second event. 16 That said, patients with a history of severe HZ are often the most insistent on receiving the vaccine,17 and concerns have been raised about the validity of patient histories of HZ. For ...
edible vaccine: a better way for immunization
... distinguishing characters to identify between ‘vaccine fruit’ and ‘normal fruit’ to avoid misadministration of vaccine which could lead to tolerance. 17. Glycosylation pattern of plants and humans is different which could affect the functions of vaccines. Applications of edible v ...
... distinguishing characters to identify between ‘vaccine fruit’ and ‘normal fruit’ to avoid misadministration of vaccine which could lead to tolerance. 17. Glycosylation pattern of plants and humans is different which could affect the functions of vaccines. Applications of edible v ...
caprisa 004 tenofovir gel trial
... halted the trial if there was compelling evidence for the treatment’s effectiveness or if a reliable result was unlikely to be realized by the end of the trial. What happened when a participant acquired HIV during the study? CAPRISA 004 was conducted in settings where there is a high background HIV ...
... halted the trial if there was compelling evidence for the treatment’s effectiveness or if a reliable result was unlikely to be realized by the end of the trial. What happened when a participant acquired HIV during the study? CAPRISA 004 was conducted in settings where there is a high background HIV ...
Viral Binding and Fusion—The Next Targets in - IAS-USA
... Characteristics of HIV Binding and Fusion It has long been recognized that HIV entry into susceptible cells involves the interaction of CD4 molecules on the host cell surface with the HIV envelope glycoproteins gp120 and gp41. More recently, it was found that interaction of the virus with coreceptor ...
... Characteristics of HIV Binding and Fusion It has long been recognized that HIV entry into susceptible cells involves the interaction of CD4 molecules on the host cell surface with the HIV envelope glycoproteins gp120 and gp41. More recently, it was found that interaction of the virus with coreceptor ...
Peer-reviewed Article PDF
... HIV genetic material remains in two forms, as two copies of single stranded RNA inside the intact viral particles and as a double stranded DNA integrated in the host genome. This double stranded DNA also known as proviral DNA. The size of HIV genome is around 9.7 KB. The proviral DNA have two long t ...
... HIV genetic material remains in two forms, as two copies of single stranded RNA inside the intact viral particles and as a double stranded DNA integrated in the host genome. This double stranded DNA also known as proviral DNA. The size of HIV genome is around 9.7 KB. The proviral DNA have two long t ...
7_Hepatitis B and C
... with and without HIV. With monotherapy with either of these two drugs HBV drug resistance develops in - 50% of patients after 2 years - 90% after 4 years of treatment. After one year of treatment HBeAg-positive HIV-1-infected individuals seroconversion characterized by loss of HBeAg and development ...
... with and without HIV. With monotherapy with either of these two drugs HBV drug resistance develops in - 50% of patients after 2 years - 90% after 4 years of treatment. After one year of treatment HBeAg-positive HIV-1-infected individuals seroconversion characterized by loss of HBeAg and development ...
GenoSure Archive : Cell-associated Viral DNA Assay for
... resistance was first documented and described in the early 1990s when the use of AZT as monotherapy was common.5-7 Drug resistance has since been described for all ARV drugs approved for HIV-1 treatment.8 Consequently, the Department of Health and Human Services recommends screening for drug resista ...
... resistance was first documented and described in the early 1990s when the use of AZT as monotherapy was common.5-7 Drug resistance has since been described for all ARV drugs approved for HIV-1 treatment.8 Consequently, the Department of Health and Human Services recommends screening for drug resista ...
Steven J. Shoptaw, Ph.D. - USA (D202.2)
... • Preclinical work shows efficacy in protecting against HIV transmission in mice and nonhuman primates • 2,441 MSM followed to 12-months for seroconversion ...
... • Preclinical work shows efficacy in protecting against HIV transmission in mice and nonhuman primates • 2,441 MSM followed to 12-months for seroconversion ...
ARV-based Microbicides and Resistance
... Assess potential long-term effects of exposure to study product among women who become infected with HIV while taking part in MTN trials Characterize the natural history of HIV infection and response to ART Assess differences in clinical progression and response to ART among women assigned to an ...
... Assess potential long-term effects of exposure to study product among women who become infected with HIV while taking part in MTN trials Characterize the natural history of HIV infection and response to ART Assess differences in clinical progression and response to ART among women assigned to an ...
Management of HIV and tuberculosis coinfection
... • No drug-drug interaction studies in pregnant women • Limited drug-drug interactions studies in children • Triple nucleoside therapy may be used when options are severely limited ...
... • No drug-drug interaction studies in pregnant women • Limited drug-drug interactions studies in children • Triple nucleoside therapy may be used when options are severely limited ...
HIV vaccine
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced.One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials.